Financial Performance - The revenue for the six months ended June 30, 2023, was RMB 5,114,026 thousand, an increase from RMB 3,205,932 thousand for the same period in 2022, representing a growth of approximately 59.5%[2] - Gross profit for the same period was RMB 1,089,275 thousand, compared to RMB 605,460 thousand in 2022, indicating a gross margin improvement[2] - The net profit attributable to equity holders of the parent company was RMB 244,669 thousand, up from RMB 270,596 thousand in the previous year, with basic and diluted earnings per share both at RMB 0.31[3] - The total segment profit for the six months ended June 30, 2023, was RMB 727,214 thousand, compared to RMB 378,269 thousand for the same period in 2022[12][13] - The company reported a pre-tax profit of RMB 625,126 thousand for the six months ended June 30, 2023[12] - The consolidated net profit for the reporting period was RMB 488 million, up from RMB 271 million in the same period last year, reflecting an increase of 80.4%[42] - The profit contribution from the self-owned hospital segment was RMB 646 million, reflecting a 131.8% increase compared to the previous year[54] - The group recorded a net profit of RMB 487 million, an increase of 79.9% year-on-year, with RMB 257 million contributed by the Liaojian and Jiangneng targets[60] Assets and Liabilities - Total non-current assets as of June 30, 2023, amounted to RMB 10,902,214 thousand, slightly down from RMB 11,051,287 thousand at the end of 2022[4] - Current assets increased to RMB 7,602,176 thousand from RMB 6,766,287 thousand, driven by an increase in trade receivables[4] - Total assets decreased to RMB 8,940,075 thousand from RMB 12,693,264 thousand, reflecting a significant reduction in total equity[5] - Total liabilities as of June 30, 2023, were RMB 11,325,340 thousand, including interest-bearing bank loans of RMB 2,434,037 thousand[15] - The total liabilities of the group amounted to RMB 7.163 billion, with current liabilities at RMB 5.124 billion[41] Cash Flow and Financial Management - The company reported a net current liability of RMB (1,962,139) thousand as of June 30, 2023, compared to a net current asset of RMB 1,641,977 thousand at the end of 2022[5] - The group has unutilized bank credit facilities of approximately HKD 2.93 billion and RMB 2.38 billion (approximately RMB 5.08 billion) as of June 30, 2023[7] - The board has reviewed the cash flow forecast for the next twelve months and believes that the group will have sufficient credit to repay its debts[7] - The company’s cash and cash equivalents, along with pledged deposits, totaled RMB 4,003,347 thousand as of June 30, 2023[15] - The company has a total credit facility of HKD 5.2 billion from overseas banks, with HKD 1.1 billion being a five-year committed loan and HKD 3 billion being a revolving credit facility[64] Operational Highlights - The company is primarily engaged in providing comprehensive medical services and hospital management services in mainland China[6] - The company managed and operated 146 medical institutions across 10 provinces and cities in China as of June 30, 2023[43] - The outpatient visits and inpatient admissions for the group’s member hospitals increased by 5.3% and 9.7% year-on-year, totaling approximately 7.1 million and 310,000 visits, respectively[43] - The total number of hospitals operated increased to 146, with a breakdown of 13 tertiary hospitals, 27 secondary hospitals, and 48 primary hospitals[44] - Inpatient services generated revenue of RMB 2,880,905 thousand, while outpatient services contributed RMB 1,863,619 thousand[20] Strategic Initiatives - The company aims to expand its market presence and enhance its service offerings through strategic initiatives in the healthcare sector[6] - The company plans to expand its market presence and enhance its service offerings through new product development and strategic acquisitions[48] - The group plans to enhance its capital structure and pursue mergers and acquisitions of quality hospitals to achieve its strategic goals during the 14th Five-Year Plan[63] - The company is focusing on market expansion and new product development, which are expected to drive future revenue growth and enhance competitive positioning[37] Accounting and Reporting - The group has adopted new accounting policies in 2023, including IFRS 17 on insurance contracts and amendments to IAS 1 and IAS 8, which did not have a significant impact on the financial statements[8] - The financial data is presented in RMB, rounded to the nearest thousand, and is based on historical cost conventions, except for certain financial assets measured at fair value[7] - The group applies the equity method for accounting for business combinations under common control, recognizing acquired assets and liabilities at their previous carrying amounts[9] - The group has not applied any new standards or interpretations that are not yet effective during the reporting period[8] Employee and Operational Challenges - Employee costs for the reporting period were approximately RMB 1.667 billion, compared to RMB 0.952 billion for the corresponding period[67] - The company employed a total of 20,189 full-time employees as of June 30, 2023, down from 20,622 employees as of December 31, 2022[67] - The company is facing talent shortages and is implementing measures to attract and retain qualified medical personnel to ensure the stability of its hospital operations[66] Governance and Compliance - The company is a limited liability company registered in the Cayman Islands on February 28, 2013[74] - The company is listed on the Hong Kong Stock Exchange[78] - The board of directors includes executive directors Song Qing, Yu Hai, Shan Baojie, and Yang Min, along with non-executive director Hu Hui and independent non-executive directors Hu Dingxu, Kuang Guoguang, and Fu Tingmei[80] - The announcement date is August 22, 2023, indicating recent developments in the company[80] - The company has no significant contingent liabilities or guarantees that would materially affect its financial position as of June 30, 2023[67]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不對因本公告全部或任何部 分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 China Resources Medical Holdings Company Limited 華潤醫療控股有限公司 （於開曼群島註冊成立的有限責任公司） （股份代號：1515） 補充公告 有關截至2022年12月31日止年度報告 之進一步資料 茲提述華潤醫療控股有限公司（「本公司」）於2023年4月24日刊發的截至2022年12月 31日止財務年度的年度報告（「2022年報」）。除文義另有所指外，本公告所用詞彙與 2022年報所界定者具有相同涵義。 董事會謹此提供有關2022年報的進一步資料如下： 採納若干估值方法的原因 根據2022年報，本公司分別採用了(i)貼現現金流量模型；及(ii)預期信貸虧損模型以 評估淮陰醫院商譽和應收款項之減值。 計提商譽減值撥備 — 貼現現金流量模型 本公司管理層持續審查商譽的減值撥備並通常按年審查，如若出現任何可能導致潛 在減值的事件或情況變化，則審查頻率會相應提高。 ...

Business Model and Strategy - In 2022, the company adjusted its business model from focusing on operational efficiency to a sustainable development model known as "1+X," aiming to enhance medical technology and create more value for public health[16]. - The new development model is expected to lead to high-quality and sustainable growth, with a focus on creating reasonable surpluses[16]. - The company is committed to strengthening supply chain management and financial resources to support its new business strategy[16]. - The Group aims to complete the acquisition of Liaojian and Jiangneng projects and focus on merging quality state-owned hospitals[25]. - The Group's strategy includes expanding its business scale and establishing an efficient regional medical system[25]. - The Group plans to enhance profitability by improving medical service quality and operational efficiency while focusing on core functions such as strategy and finance[102]. Financial Performance - The annual medical business income totaled RMB8.336 billion, representing a slight increase of 0.8% year-on-year[19]. - The net profit attributable to the owners of the parent was RMB139 million, a year-on-year decrease of 66.7% due to operating losses and impairments from the acquisition of Huaiyin Hospital[19]. - The Group recorded a net profit of RMB159 million, a decrease of 62.6% year-on-year, primarily due to operating losses and exchange losses[30]. - The Group's net profit for the Reporting Period was RMB159 million, representing a year-on-year decrease of approximately 62.6%[81]. - The Group's income tax expenses amounted to RMB83 million during the Reporting Period, compared to a credit figure of RMB155 million in FY2021[80]. - The Group's total staff cost for FY2022 was approximately RMB 1.78 billion, an increase from RMB 1.18 billion in FY2021, attributed to the consolidation of certain hospitals[130]. Operational Metrics - The Group's annual outpatient visits increased by 2.1% year-on-year, while inpatient visits rose by 1.5%[19]. - The Group managed and operated 116 medical institutions across 8 provinces, with annual outpatient visits reaching approximately 15.27 million, a 41.6% increase from 2021[32]. - The total number of patients treated in 2022 was 15,266,657, reflecting a significant operational scale[42]. - The total number of operational beds was 11,115 with an overall utilization rate of 73%[42]. - The number of outpatient visits reached 15,266,657, while inpatient visits totaled 286,152, contributing to a total medical business revenue of RMB 8,336,458,000[42]. Revenue Breakdown - Revenue from self-owned hospitals was RMB 5,178,404,000, while IOT/OT hospitals generated RMB 430,637,000 in revenue[48]. - The revenue from the self-owned hospital segment increased by 0.9% year-on-year to approximately RMB 6.76 billion, while segment results decreased by 14.7% to approximately RMB 437 million[55]. - The revenue from outpatient visits was RMB 4,158,753,000, and inpatient visits generated RMB 4,021,749,000[48]. - The revenue from general healthcare services increased significantly by 108.3% to RMB 287 million[60]. Challenges and Impairments - The Group experienced a 10% increase in the number of patients treated compared to the previous year[41]. - The Group did not have any significant investments accounting for 5% or more of total assets as of December 31, 2022[89]. - For the fiscal year ended December 31, 2022, the Company recorded a provision for goodwill impairment of approximately RMB108 million due to the gradual loss of medical staff at Huaiyin Hospital, which significantly impacted its operations[73]. - Huaiyin Hospital's medical business revenue dropped by more than 50% year-on-year in 2022, resulting in an operating loss of approximately RMB76 million[73]. Employee and Talent Management - The total number of full-time employees increased to 9,668 as of December 31, 2022, from 8,454 in the previous year[130]. - Employee costs for the fiscal year 2022 amounted to approximately RMB 1.78 billion, up from RMB 1.18 billion in the fiscal year 2021, attributed to the consolidation of several hospitals during the year[133]. - The Group is committed to providing a safe and harassment-free working environment for employees, emphasizing workplace safety throughout the year[165]. - The Group has implemented a talent attraction program in response to the attrition of medical staff at Huaiyin Hospital to improve operations[73]. Environmental and Governance Policies - The Group has implemented environmental policies in compliance with PRC laws, with no material environmental claims or penalties reported during the year ended December 31, 2022[151]. - The Group has established a "Hazardous Substances Safety Management Plan" and a "Medical Waste Management System" for all hospitals to manage hazardous materials and medical waste[152]. - The Group's environmental, social, and governance report will be published alongside the annual report, detailing measures taken in these areas[160]. Dividends and Shareholder Information - The Group proposes a 2022 Final Dividend of 3.7 HK cents per Share, down from 12 HK cents in FY2021, totaling approximately HK$48 million[171]. - The Group's ability to pay dividends is contingent on its financial condition, operations, liquidity, and capital requirements[174]. - The company has no assurance that dividends will be paid in any particular amount for any given period[179].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示概不對因本公告全部或任何部分內容而 產生或因倚賴該等內容而引致的任何損失承擔任何責任。 China Resources Medical Holdings Company Limited 華潤醫療控股有限公司 （於開曼群島註冊成立的有限責任公司） （股份代號：1515） 截至2022年12月31日止年度全年業績公告 | --- | --- | --- | |--------------------------------------------------|-----------|-----------| | | | | | 財務摘要 | 2022 年 | 2021 年 | | | | | | 收益（人民幣千元） | 5,620,461 | 4,447,477 | | 母公司擁有人應佔年度利潤（人民幣千元） | 138,974 | 417,915 | | 母公司普通股權益持有人應佔每股盈利（基本及攤薄） | | | | （人民幣） | 0.11 | 0.33 | | 建議分派之每股末期股息（港 ...

Financial Performance - The consolidated revenue for the reporting period amounted to RMB 2,850 million, a year-on-year increase of 60.8% from RMB 1,772 million[12]. - Net profit for the reporting period was RMB 215 million, slightly up from RMB 205 million in the corresponding period, indicating stable growth[12]. - Earnings per share remained unchanged at RMB 0.16 compared to the previous period[12]. - Total revenue from medical business for H1 2022 reached RMB 4,017,215, an increase from RMB 3,287,449 in the corresponding period[22]. - The net profit for H1 2022 was RMB 214,747, compared to a loss of RMB 5,740 in the corresponding period[22]. - The Group recorded a net profit of RMB 215 million, representing a year-on-year increase of 4.6%[41]. - Revenue for the six months ended June 30, 2022, was RMB 2,850,489, an increase of 61% compared to RMB 1,772,123 for the same period in 2021[118]. - Gross profit for the same period was RMB 524,266, representing a gross margin of approximately 18.4%[118]. - Profit before tax for the six months ended June 30, 2022, was RMB 254,175, a decrease of 5.9% from RMB 270,142 in the prior year[118]. - Comprehensive income for the period was RMB 214,747, compared to RMB 205,325 for the same period in 2021, indicating a slight increase[118]. Operational Metrics - The total number of outpatient visits increased by 66.1% to approximately 7.87 million, while inpatient visits rose by 11.4% to around 143,000[15]. - The number of operational beds increased to 11,369 with an overall utilization rate of 70.7%[19]. - Out-patient visits totaled 7,869,968, while in-patient visits were 142,877 for H1 2022[19]. - Total number of patients treated in H1 2022 was 7,869,968, with 4,941,511 being out-patients[19]. - The utilization rate of self-owned hospitals was 73.7%, while IOT/OT hospitals had a utilization rate of 51.6%[19]. Revenue Breakdown - Revenue from out-patient visits was RMB 1,996,751, and revenue from in-patient visits was RMB 1,971,362[22]. - Total revenue from medical business for self-owned hospitals increased by 7.7% year-on-year to approximately RMB 3.29 billion[29]. - The segment results for self-owned hospitals recorded a decrease of 1.7% to approximately RMB 265 million[31]. - IOT/OT hospitals segment achieved a 0.9% increase in medical business revenue, totaling RMB 729,766[34]. - IOT/OT hospitals segment results increased by 19.2% to RMB 58,843[34]. - Revenue from general healthcare services and hospital management services increased by 46.6% to RMB 121,373[32]. Expenses and Costs - The company reported administrative expenses of RMB 256,204, an increase from RMB 237,078 in the previous period[22]. - Total operating expenses of the headquarters decreased to approximately RMB 36 million, accounting for 12.4% of total administrative expenses[35]. - Staff costs for the reporting period were approximately RMB 836 million, a significant increase from RMB 471 million in the corresponding period[63]. - Selling and distribution expenses were RMB 8,779, while administrative expenses totaled RMB 292,473, indicating an increase in operational costs[118]. - The Group's profit before tax for the six months ended 30 June 2022 was significantly impacted by a cost of inventories sold amounting to RMB 1,476,492, an increase of 59.7% compared to RMB 924,993 in 2021[198]. Assets and Liabilities - The total assets as of June 30, 2022, were reported at RMB 5,000,000, compared to RMB 4,500,000 as of December 31, 2021, showing a growth in asset base[119]. - Total non-current assets increased to RMB 6,708,546, up from RMB 6,543,020, representing a growth of approximately 2.52%[120]. - Current assets rose to RMB 4,154,816, compared to RMB 3,924,582, reflecting an increase of about 5.86%[120]. - Total non-current liabilities surged to RMB 1,123,016, compared to RMB 177,423, indicating a dramatic rise[122]. - Total liabilities as of June 30, 2022, amounted to RMB 3,621,157, with interest-bearing bank borrowings at RMB 1,646,624[178]. Strategic Initiatives - The Group's strategic expansion includes the consolidation of additional medical institutions into its operations, enhancing its market presence[13]. - Future plans include enhancing the "RUNXIN" patient service system and modernizing hospital operations to improve service quality[53]. - The Group aims to improve operational efficiency and medical service quality through policy research on medical insurance payment reform and timely measures[55]. - The Group plans to seize merger and acquisition opportunities during the state-owned hospital reform period to accelerate growth[55]. - The Group recognizes the importance of maintaining relationships with patients and partners for sustainable development[62]. Governance and Compliance - The Company confirmed compliance with all material code provisions of the Corporate Governance Code during the reporting period[71]. - The risk management and internal control systems are designed to protect the Group's assets and ensure compliance with relevant laws and regulations[74]. - The Board will continue to optimize risk management and internal control systems in line with business development[80]. - The Group has performed annual impairment reviews of sponsorship rights, service contracts, and goodwill, concluding no impairment was required as of June 30, 2022[85]. Shareholder Information - China Resources Company Limited holds 474,319,516 shares, representing approximately 36.58% of the total issued shares[104]. - Mitsubishi UFJ Financial Group, Inc. holds 77,645,666 shares, accounting for about 5.98% of the total issued shares[104]. - The Board did not recommend the payment of any interim dividend for the reporting period, consistent with the corresponding period[68]. - No share options were granted, exercised, cancelled, or lapsed during the reporting period, and there are no outstanding share options under the Share Option Scheme[89].

Financial Performance - The Group recorded a net profit attributable to the parent of RMB418 million, an increase of 34.8% year-on-year and 6.9% compared to 2019[15]. - Total medical business revenue was RMB8,272 million, representing a rise of 24.5% year-on-year and a 20.4% increase compared to 2019[15]. - The Group achieved a consolidated revenue of RMB 4,447 million for the year ended December 31, 2021, representing a 61.6% increase from RMB 2,751 million in 2020 and a 109.8% increase from RMB 2,115 million in 2019[31]. - The net profit for the Group was RMB 426 million in 2021, up 33.1% from RMB 320 million in 2020 and a slight increase of 6.2% from RMB 401 million in 2019[32]. - The Group recorded a net profit of RMB 426,000,000 in 2021, representing a year-on-year increase of approximately 33%[95]. - The Group's earnings per share increased to RMB 0.33 in 2021, up from RMB 0.25 in 2020 and RMB 0.31 in 2019[32]. Operational Metrics - In 2021, the number of outpatient visits to member hospitals increased by 39.9% year-on-year and by 22.8% compared to 2019[15]. - The number of inpatient visits grew by 28.3% year-on-year and by 11.7% compared to 2019[15]. - The outpatient volume of member hospitals increased by 39.9% year-on-year and by 22.8% compared to 2019, while inpatient volume grew by 28.3% year-on-year and by 11.7% compared to 2019[17]. - The annual number of inpatient visits was approximately 282,000, reflecting an increase of 28.3% compared to 2020[37]. - The Group's member hospitals have shown a consistent trend of increasing operational metrics, indicating a positive outlook for future performance[40]. Strategic Initiatives - The company aims to be a leading healthcare group in China and a pioneer in the reform of state-owned medical institutions as part of its 14th Five-Year strategic plan[13]. - The Group aims to establish regional leading hospital clusters and academic specialty hospital clusters during the 14th Five-Year Plan, focusing on organic growth and external expansion[25]. - The Group plans to enhance medical technology, quality, and service capabilities to achieve high-quality growth and boost commercial value through group management and efficiency improvements[26]. - The company expressed gratitude to shareholders, staff, and frontline medical workers for their support during the pandemic[14]. Acquisitions and Consolidations - The Group consolidated the financial statements of Guangdong 999 Brain Hospital and Xukuang Hospital starting from August 2021, enhancing the reflection of business performance in financial statements[24]. - The acquisition of Huaiyin Hospital, a Grade II comprehensive for-profit hospital, was completed in June 2021, further expanding the Group's presence in the Yangtze River Delta region[20]. - The Group completed the acquisition of Huaiyin Hospital, which has been consolidated into the Group's financial statements since June 2021[38]. - The acquisitions of Jinan Zhongqi Hospital and Huaiyin Hospital contributed to the revenue growth in the self-owned hospitals segment[76]. Employee and Operational Management - As of December 31, 2021, the Group had a total of 8,454 full-time employees, an increase from 4,903 employees as of December 31, 2020[133]. - For FY2021, the staff cost was approximately RMB 1.18 billion, up from RMB 685 million in FY2020, primarily due to the acquisition and consolidation of certain hospitals[133]. - The Group has taken measures to attract, train, and retain qualified medical personnel to mitigate talent risk[130]. - The Group emphasizes the importance of relationships with patients and partners for sustainable business development[130]. Financial Position and Investments - As of December 31, 2021, the Group's consolidated bank balances and cash amounted to approximately RMB 3.23 billion, an increase from RMB 3.09 billion as of December 31, 2020[115]. - The Group's interest-bearing bank borrowings totaled approximately RMB 1.65 billion as of December 31, 2021, compared to approximately RMB 684 million as of December 31, 2020, indicating a significant increase[116]. - The Group's gearing ratio was 15.9% as of December 31, 2021, up from 7.6% as of December 31, 2020, reflecting increased leverage[117]. - The Group's investment in joint ventures and associates contributed a profit of RMB 83,553,000 during the reporting period[68]. Corporate Social Responsibility and Compliance - The Group has implemented strict environmental policies and complied with all relevant PRC laws regarding environmental protection during the year[151]. - The Group has developed various safety management plans, including the "Hazardous Substances Safety Management Plan" and "Medical Waste Management System" to ensure compliance with environmental regulations[152]. - The Group considers its employees as key to sustainable business growth and maintains a high standard of health and safety measures[165]. - The Group emphasizes a commitment to employee safety and equal opportunities, integrating these principles into its corporate responsibility policies[168]. Dividend and Shareholder Information - The Group proposes a final dividend of 12 HK cents per share for FY2021, an increase from 8.82 HK cents in FY2020, totaling approximately HK$156 million[171][175]. - The Group's ability to pay dividends is subject to its financial condition, operations, liquidity, and capital requirements[174][177]. - As of December 31, 2021, the Company's share premium amounted to RMB5,785,472,000, down from RMB5,877,796,000 in 2020, available for distribution to shareholders[183][189].

Financial Performance - The consolidated revenue for the six months ended June 30, 2021, amounted to RMB 1,772 million, a 95.2% increase from RMB 907 million in the same period last year[8]. - Net profit for the period was RMB 205 million, up 86.4% from RMB 110 million in the same period last year[8]. - Earnings per share increased to RMB 0.16, compared to RMB 0.09 in the same period last year[8]. - The total revenue from medical business for the first half of 2021 was RMB 3,777.148 million, with RMB 1,138.886 million from consolidated hospitals, RMB 1,914.703 million from unconsolidated hospitals, and RMB 723.559 million from IOT/OT hospitals[18]. - The group reported a net profit of RMB 205.325 million for the first half of 2021, with administrative expenses amounting to RMB 127.506 million[18]. - The financial results demonstrate a robust growth trajectory in the medical business, highlighting the effectiveness of the group’s expansion strategies[18]. - The effective control of the COVID-19 epidemic has led to a satisfactory recovery of operations and growth in revenue across the Group's member medical institutions[25]. - The Group recorded a net profit of RMB 205 million, representing an increase of 86.3% year-on-year[42]. - The company reported a significant increase in other income, which rose to RMB 54,697 from RMB 38,779, indicating improved operational efficiency[126]. - The company reported a fair value loss on financial assets at FVTPL of RMB 21,876,000, impacting overall profitability[167]. Operational Metrics - The overall number of out-patients and in-patients increased by 50.5% and 36.8%, respectively[8]. - The group operated 11,097 beds with an overall bed utilization rate of 71.6% during the first half of 2021, accommodating 128,270 inpatients[14][18]. - The revenue from outpatient visits was RMB 1,784.523 million, while inpatient visits generated RMB 1,928.301 million in revenue during the same period[18]. - The group’s outpatient and inpatient visit numbers reflect a significant operational scale, indicating strong demand for healthcare services[12][13]. - The segment results for unconsolidated hospitals showed a profit of RMB 154,745,000, indicating healthy operational performance[167]. Acquisitions and Expansions - On March 28, 2021, the company agreed to acquire approximately 99.19% of Huaiyin Hospital for a consideration of approximately RMB 880 million[9]. - The acquisition of Huaiyin Hospital was completed on June 17, 2021, and its financial statements have been consolidated into the Group[9]. - Jianghua Management Limited acquired 99.19% of Sinophi China Hospitals Limited for approximately RMB 880 million, completing the acquisition on June 17, 2021[11]. - The acquisition of Huaiyin Hospital indirectly increased the group’s operational capacity, as the hospital has approximately 1,190 open beds[11]. - The Group aims to enhance its core medical services and develop six discipline clusters, including cardiovascular and oncology, to strengthen its brand in these areas[55][57]. Financial Position - As of June 30, 2021, the group managed a total of 123 medical institutions across 8 provinces and cities in China, with approximately 4.739 million outpatient visits and 128,000 inpatient visits during the reporting period[12][13]. - As of June 30, 2021, the Group's consolidated bank balances and cash amounted to approximately RMB 2.49 billion, down from approximately RMB 3.09 billion as of December 31, 2020[60]. - The Group's gearing ratio as of June 30, 2021, was 16.3%, an increase from 7.6% as of December 31, 2020[61]. - Total non-current assets as of June 30, 2021, amounted to RMB 6,519,806, an increase from RMB 4,816,301 as of December 31, 2020[130]. - Total current assets were RMB 3,806,706, down from RMB 4,146,892 at the end of 2020, indicating a decrease in liquidity[130]. - Net current assets decreased to RMB 566,964 from RMB 1,939,706, highlighting a potential liquidity concern[130]. - Total liabilities were reported at RMB 3,705,924,000, including interest-bearing bank borrowings of RMB 1,663,511,000[177]. Staff and Management - As of June 30, 2021, the Group had a total of 6,097 full-time employees, an increase from 4,903 employees as of December 31, 2020, primarily due to the acquisition of Huaiyin Hospital[67]. - Staff costs for the six months ended June 30, 2021, were approximately RMB 471 million, compared to RMB 205 million for the same period in 2020, reflecting a significant increase[67]. - The Board did not recommend the payment of any interim dividend for the six months ended June 30, 2021, consistent with the previous year[71]. Risk Management and Compliance - The Group's risk management and internal control systems are designed to protect assets and ensure compliance with laws and regulations[82]. - The Audit Committee reviewed the unaudited consolidated interim results and confirmed compliance with relevant accounting standards and legal requirements[77]. - The Company confirmed compliance with all material code provisions of the Corporate Governance Code during the reporting period[75]. Future Strategies - The Group plans to improve operational efficiency and reduce costs while expanding existing hospitals and pursuing mergers and acquisitions[55][57]. - Future strategies include enhancing operational efficiencies and exploring potential acquisitions to strengthen market position[170].

華潤醫療控股有限公司 China Resources Medical Holdings Company Limited (Incorporated in the Cayman Islands with limited liability) (於開曼群島註冊成立之有限責任公司) Stock Code 股票代號 :1515 2020 年度報告 ANNUAL REP O R T 變局中 上下同欲者 開新局 勝 華潤醫療控股有限公司 China Resources Medical Holdings Company Limited 2 020 年度報告 Annual R eport CONTENTS 目錄 2 Corporate Information 公司資料 5 Chairman's Statement 董事長報告 8 Management Discussion and Analysis 管理層討論與分析 30 Directors' Report 董事會報告 64 Corporate Governance Report 企業管治報告 83 Directors and Senior Management 董事及高級管 ...

Financial Performance - The consolidated revenue for the six months ended June 30, 2020, was RMB 907 million, a decrease of 6.0% compared to RMB 965 million in the same period last year[11]. - Net profit for the period was RMB 110 million, down 41.6% from RMB 189 million in the previous year, with earnings per share of RMB 0.09 compared to RMB 0.15[11]. - The total revenue from medical business of member hospitals decreased by 18.0% to approximately RMB 2.702 billion during the reporting period[12]. - In H1 2020, the total number of operational beds was 10,872, with an overall bed utilization rate of 57.1%[29]. - Revenue from medical business in H1 2020 amounted to RMB 2,702,450,000, with outpatient revenue at RMB 1,313,679,000 and inpatient revenue at RMB 1,356,412,000[33]. - The Group's net profit was RMB 110 million, reflecting a year-on-year decrease of 41.5%[60]. - Profit before tax decreased to RMB 156,191,000, representing a decline of 38.5% from RMB 253,941,000 in the previous year[143]. - Comprehensive income for the period was RMB 110,220,000, down 41.5% from RMB 188,524,000 in 2019[143]. - The Group's consolidated hospitals included Jinan Zhong Qi Hospital from April 2020, contributing to the overall financial performance[34]. - The overall medical business revenue of the unconsolidated hospital segment decreased by 32.3% year-on-year to approximately RMB1.174 billion, with segment profit decreasing by 54.9% to approximately RMB47.84 million, also impacted by COVID-19[45]. Operational Impact of COVID-19 - The company implemented strict COVID-19 prevention measures, including the formation of an emergency team led by the CEO to manage the epidemic response[13]. - No medical staff from member hospitals have been infected by COVID-19 as of the date of the report[16]. - The management emphasized the importance of employee health and well-being, implementing measures to support their physical and psychological health[16]. - During the reporting period, the total number of inpatient and outpatient visits to member hospitals decreased by 26.3% and 23.7% respectively due to the epidemic[20]. - The emergency supply team established by CR Medical ensured sufficient supply of prevention and control materials to member institutes during the tight supply situation[18]. - The number of patients at member hospitals rebounded significantly in May 2020, indicating a recovery in business operations[20]. - The company has implemented measures to address the impact of COVID-19, which affected the overall performance and profitability of member hospitals during the reporting period[38]. Employee and Management Measures - The management team and all medical staff postponed their leave and remained on duty during the epidemic[20]. - The Group had a total of 4,843 full-time employees as of June 30, 2020, a significant increase from 1,178 employees as of December 31, 2019[81]. - Employee costs for the six months ended June 30, 2020, amounted to approximately RMB 205 million, compared to RMB 162 million for the same period in 2019, reflecting a year-on-year increase of 26.5%[84]. - The Group's employee count in non-consolidated hospitals was 4,300 as of June 30, 2020, down from 7,422 as of December 31, 2019[84]. Financial Position and Assets - As of June 30, 2020, the Group's consolidated bank balances and cash amounted to approximately RMB2.905 billion, an increase from RMB2.276 billion as of December 31, 2019[71]. - Total non-current assets as of June 30, 2020, amounted to RMB 4,658,006,000, a slight decrease from RMB 4,675,772,000 at the end of 2019[145]. - Total current assets increased to RMB 3,908,106,000 from RMB 3,198,209,000 at the end of 2019, reflecting a growth of 22.2%[145]. - Total liabilities were recorded at RMB 2,342,153,000, with segment liabilities from consolidated hospitals at RMB 821,599,000[190]. - The company reported financial assets at fair value through profit or loss (FVTPL) totaling RMB 1,585,187,000, indicating a strong investment position[190]. Strategic Plans and Future Outlook - The Group aims to complete the restructuring of Jing Mei Hospital in the third quarter of 2020[70]. - Future plans include capital requirements for the proposed reform of Jing Mei Hospital Group and further investments in Jinan Zhong Qi Hospital[67]. - The Group plans to advance the specialized reform of two hospitals in South China within the year[70]. - The company is focusing on expanding its GPO business and enhancing its hospital management services to drive future growth[180]. - Future outlook remains cautious due to market uncertainties, but strategic expansions are planned[199]. Governance and Compliance - The Board confirmed compliance with all material code provisions of the Corporate Governance Code during the review period[89][90]. - The Board has reviewed the efficiency of the Group's risk management and internal control systems across various aspects, including financial and operational areas[95]. - The Group's risk management and internal control systems are designed to protect assets and ensure compliance with relevant laws and regulations[93][94]. - There were no significant contractual obligations that would materially impact the Group's financial position or operations as of June 30, 2020[85]. Segment Performance - The Group is organized into four reportable operating segments: Consolidated hospitals, Unconsolidated hospitals, IOT/OT hospitals, and Others, for management purposes[170]. - Segment performance is evaluated based on reportable segment profit/loss, which is adjusted profit/loss before tax, excluding certain items like share of profits and losses of joint ventures[170]. - Consolidated segment results totaled RMB 290,213,000 for the period, with contributions from consolidated hospitals at RMB 54,741,000, unconsolidated hospitals at RMB 106,088,000, and IOT/OT hospitals at RMB 121,831,000[186].

(Incorporated in the Cayman Islands with limited liability) China Resources Medical Holdings Company Limited 華潤醫療控股有限公司 (於開曼群島註冊成立之有限責任公司) Stock Code 股票代號 :1515 二零一九年報 ANNUAL REPORT 2019 華潤醫療控股有限公司 China Resources Medical Holdings Company Limited 2 019 年 報 Annual R eport C M Y CM MY CY CMY K China Resources Medical AR 2019 fullcover(20.6mm)OP.pdf 1 20/4/2020 下午5:43 CONTENTS 目錄 2 Corporate Information 公司資料 5 Chairman's Statement 董事長報告 8 Management Discussion and Analysis 管理層討論與分析 26 Directors' Report 董事會報告 6 ...